CRSPCRISPR Therapeutics

Each row is one issuer’s token for CRISPR Therapeutics, with the chains it is deployed on. A bold chain is one where these wallets hold a balance. Tokens are not shares: no issuer in the registry publishes a shares-per-token ratio, so a balance is counted one per share and marked where that assumption is doing work.

Tokenized versions of CRISPR Therapeutics, the issuer behind each, the chains it is deployed on, and what these wallets hold of it.

Token	Issuer	Chains	You hold
rCRSP	Reality	ARBMRPH	—

Deployments come from the instrument registry, generated 2026-09-30. A chain listed here is one the issuer has deployed on, not a promise that a market exists on it.

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Type

Common stock

Sector

Healthcare › Biotechnology

Exchange

Nasdaq

Listed since

Oct 19, 2016

Shares outstanding

96.69M

Employees

393

As the market data provider names it. Where that differs from the issuers’ name for the security, both are shown so the difference is visible.